E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer

被引:666
|
作者
Schmalhofer, Otto [1 ]
Brabletz, Simone [1 ]
Brabletz, Thomas [1 ]
机构
[1] Univ Freiburg, Dept Visceral Surg, D-79106 Freiburg, Germany
关键词
E-cadherin; EMT; ZEB1; Cancer; Invasion; Feedback/forward loop; EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR ZEB1; ZINC-FINGER PROTEIN; HAIR FOLLICLE MORPHOGENESIS; CELL-ADHESION MOLECULE; WNT SIGNALING PATHWAY; REPRESSES E-CADHERIN; REGULATES E-CADHERIN; GROWTH-FACTOR-I; COLORECTAL-CANCER;
D O I
10.1007/s10555-008-9179-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The embryonic program 'epithelial-mesenchymal transition' (EMT) is activated during tumor invasion in disseminating cancer cells. Characteristic to these cells is a loss of E-cadherin expression, which can be mediated by EMT-inducing transcriptional repressors, e.g. ZEB1. Consequences of a loss of E-cadherin are an impairment of cell-cell adhesion, which allows detachment of cells, and nuclear localization of beta-catenin. In addition to an accumulation of cancer stem cells, nuclear beta-catenin induces a gene expression pattern favoring tumor invasion, and mounting evidence indicates multiple reciprocal interactions of E-cadherin and beta-catenin with EMT-inducing transcriptional repressors to stabilize an invasive mesenchymal phenotype of epithelial tumor cells.
引用
收藏
页码:151 / 166
页数:16
相关论文
共 50 条
  • [21] MUC1 modulation of E-cadherin through miR-200c and ZEB1
    Mohr, Ashley M.
    Lewallen, Michelle E.
    Radhakrishnan, Prakash
    Liu, Xiang
    Bailey, Jennifer M.
    Hollingsworth, Michael A.
    CANCER RESEARCH, 2012, 72
  • [22] NAC1 Regulates Somatic Cell Reprogramming by Controlling Zeb1 and E-cadherin Expression
    Faiola, Francesco
    Yin, Nuoya
    Fidalgo, Miguel
    Huang, Xin
    Saunders, Arven
    Ding, Junjun
    Guallar, Diana
    Dang, Baoyen
    Wang, Jianlong
    STEM CELL REPORTS, 2017, 9 (03): : 913 - 926
  • [23] The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2
    Park, Sun-Mi
    Gaur, Arti B.
    Lengyel, Ernst
    Peter, Marcus E.
    GENES & DEVELOPMENT, 2008, 22 (07) : 894 - 907
  • [24] E-cadherin & β-catenin expression in breast cancer:: Is there change of expression with progression of disease?
    Riding, MA
    Wencyk, PM
    Bell, JA
    Ellis, IO
    Elston, CW
    Pinder, SE
    JOURNAL OF PATHOLOGY, 2000, 192 : 19A - 19A
  • [25] Expression of HnRNP A1, ZEB1, and E-cadherin in Hepatocellular carcinoma and their impact on patients' prognosis and survival
    Abouhashem, Nehal S.
    Elwan, Amira
    El Hefnawy, Ahmed S.
    Atwa, Hanaa A.
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2022, 65 (03) : 589 - 597
  • [26] Alterations of E-cadherin and β-catenin in gastric cancer
    Chen Huiping
    Sigrun Kristjansdottir
    Jon G Jonasson
    Jonas Magnusson
    Valgardur Egilsson
    Sigurdur Ingvarsson
    BMC Cancer, 1
  • [27] Repression of E-cadherin by SNAIL, ZEB1, and TWIST in invasive ductal carcinomas of the breast: a cooperative effort?
    Montserrat, Nuria
    Gallardo, Alberto
    Escuin, Daniel
    Catasus, Lluis
    Prat, Jaime
    Jose Gutierrez-Avigno, Francisco
    Peiro, Gloria
    Barnadas, Agusti
    Lerma, Enrique
    HUMAN PATHOLOGY, 2011, 42 (01) : 103 - 110
  • [28] Cydooxygenase-2 and RhoA modulates E-cadherin expression through the transcriptional repressor ZEB1
    Bean, Ronald R.
    Jakobi, Rolf
    Chang, Yu-Wen E.
    FASEB JOURNAL, 2008, 22
  • [29] ZEB1 and oncogenic Ras constitute a regulatory switch for stimulus-dependent E-cadherin downregulation
    Otake, Shigeo
    Itoh, Yuka
    Omata, Chiho
    Saitoh, Masao
    Miyazawa, Keiji
    CANCER SCIENCE, 2021, 112 (01) : 205 - 216
  • [30] ZEB1 Collaborates with ELK3 to Repress E-Cadherin Expression in Triple-Negative Breast Cancer Cells
    Cho, Hyeon-Ju
    Oh, Nuri
    Park, Ji-Hoon
    Kim, Kwang-Soo
    Kim, Hyung-Keun
    Lee, Eunbyeol
    Hwang, Sohyun
    Kim, Seong-Jin
    Park, Kyung-Soon
    MOLECULAR CANCER RESEARCH, 2019, 17 (11) : 2257 - 2266